source
- Oral SERDs show promise in hormone-receptor positive breast cancer, offering alternative to injectionsOral selective estrogen receptor degraders (SERDs) are being positioned as a new approach for metastatic hormone-receptor positive breast cancer because they can break down the estrogen receptor an…
- Retifanlimab plus chemo improves progression-free survival in first-line SCAC trialTopline results from the PODIUM-303 study show that adding the PD-1 inhibitor retifanlimab to carboplatin and paclitaxel improves outcomes for patients with squamous cell carcinoma of the anal cana…onclive · 3mo agoPositive readoutPositive